Abstract:Aberrant sialylation functions as an important modulator of all steps of malignant transformation. Therefore, targeting sialylation regulators, such as sialyltransferases and neuraminidases, is a potential strategy for treating cancer. Here, we found that elevated α2,3-sialyltransferase III (St3gal3) was associated with dismal prognosis in high-grade serous ovarian carcinoma (HGSC). St3gal3 knockdown antagonized subcutaneous tumor growth in immunocompetent, but not immunodeficient mice, with enhanced accumulation of functional CD8+ T cells and anti-tumor immune gene signatures. St3gal3 knockdown inhibited intraperitoneal tumor growth and repolarized tumor-associated macrophages from a pro-tumorigenic M2-like to a tumor-suppressive M1-like phenotype. In vitro, St3gal3 knockdown tumor cells guided bone marrow-derived macrophages (BMDM) toward the M1-like phenotype under both direct contact and distant transwell co-culture conditions. Depletion of macrophages rescued the suppressed tumor growth induced by St3gal3 knockdown and completely suppressed infiltration of functional CD8+ T cells that rely on macrophage-derived CXCL10. St3gal3 engendered an immunosuppressive HGSC microenvironment characterized by an abundance of pro-tumorigenic macrophages and reduced cytotoxic T cell infiltration. In vivo, St3gal3 knockdown improved effectiveness of dual immune checkpoint blockade (ICB) with αPD-1 and αCTLA-4 antibodies. Preclinical inhibition of sialylation with ambroxol resulted in decreased tumor growth and prolonged the survival of tumor-bearing mice, which was enhanced by the addition of dual ICB. These findings indicate that altered sialylation induced by St3gal3 upregulation promotes a tumor suppressive microenvironment in HGSC and targeting α2,3-sialylation may reprogram the immunosuppressive tumor microenvironment and improve the efficacy of immunotherapy.

Immune Checkpoint Therapy-Elicited Sialylation of IgG Antibodies Impairs Antitumorigenic Type I Interferon Responses in Hepatocellular Carcinoma

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9

Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy

Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.

Sialic Acids Blockade‐Based Chemo‐Immunotherapy Featuring Cancer Cell Chemosensitivity and Antitumor Immune Response Synergies

Tumor Immune Checkpoints and Their Associated Inhibitors

Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy

Sialic acid and Siglec receptors in tumor immunity and immunotherapy

Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy

Specifically Editing Cancer Sialoglycans for Enhanced Immunotherapy In Vivo through Aptamer‐Enzyme Chimeras

Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2

Tumor sialylation controls effective anti-cancer immunity in breast cancer

Attenuation of sialylation augments antitumor immunity and improves response to immunotherapy in ovarian cancer

Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma

Targeted glycan degradation potentiates the anticancer immune response in vivo

Siglec‐G Suppresses CD8+ T Cells Responses through Metabolic Rewiring and Can be Targeted to Enhance Tumor Immunotherapy

Reshaping the tumor microenvironment by degrading glycoimmune checkpoints Siglec-7 and -9

Immune Checkpoint Targeting TIGIT in Hepatocellular Carcinoma.

Targeting Ibrutinib to Tumor-Infiltrating T Cells with a Sialic Acid Conjugate-Modified Phospholipid Complex for Improved Tumor Immunotherapy.